Affiliation

• ¹Department of Respiratory Disease, Daping Hospital, Third Military Medical University
• ²Chongqing Key Laboratory of Molecular Oncology and Epigenetics, First Affiliated Hospital of Chongqing Medical University

Corresponding Author

Yong He, Department of Respiratory Disease, Daping Hospital, Third Military Medical University; E-mail: heyong@dphospital.tmmu.edu.cn

Citation

He, Y., et al. The Clincal Strategy to Overcome EGFR-TKI Acquired Resistance for NSCLC Patient. (2016) Intl J Cancer Oncol 3(2): 1-4.

Copy rights

© 2016 He, Y. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.

Keywords

Abstract

  Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are current treatments for advanced non-small cell lung cancer (NSCLC) harboring activating EGFR gene mutations. Although studies show an increased progression free survival (PFS) with use of EGFR TKIs in the first-line setting, most patients will develop resistance to therapy after the first about 10 months. Undoubtedly it is critical to choose an optimal clinical strategy for patients with EGFR sensitive mutation undergoing EGFR-TKI resistance. The second biopsy should be applied under condition permission to verify specific resistance mechanism. Here we discussed the mechanism of drug resistance and the choice of therapeutic regimen, also compared the superior and inferior of each treatment plan, which proposed a novel perspective for NSCLC target therapy.